Entropy Technologies LP Makes New $1.89 Million Investment in Novartis AG $NVS

Entropy Technologies LP bought a new stake in shares of Novartis AG (NYSE:NVS) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund bought 12,359 shares of the company’s stock, valued at approximately $1,888,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BXM Wealth LLC boosted its holdings in Novartis by 726.9% during the fourth quarter. BXM Wealth LLC now owns 42,817 shares of the company’s stock worth $5,903,000 after buying an additional 37,639 shares during the last quarter. Spire Wealth Management increased its stake in shares of Novartis by 2,561.0% in the 4th quarter. Spire Wealth Management now owns 38,983 shares of the company’s stock valued at $5,375,000 after acquiring an additional 37,518 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Novartis by 14.4% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 113,737 shares of the company’s stock valued at $15,681,000 after acquiring an additional 14,352 shares during the period. HF Advisory Group LLC grew its holdings in Novartis by 401.0% during the fourth quarter. HF Advisory Group LLC now owns 54,741 shares of the company’s stock valued at $7,547,000 after purchasing an additional 43,814 shares during the period. Finally, Concurrent Investment Advisors LLC increased its stake in Novartis by 36.6% in the fourth quarter. Concurrent Investment Advisors LLC now owns 14,815 shares of the company’s stock valued at $2,043,000 after purchasing an additional 3,967 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NVS has been the subject of a number of recent analyst reports. Weiss Ratings cut shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Citigroup reaffirmed a “buy” rating on shares of Novartis in a report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $141.20.

Novartis Price Performance

Shares of NYSE NVS opened at $154.84 on Monday. The firm has a market cap of $295.46 billion, a P/E ratio of 23.35, a price-to-earnings-growth ratio of 2.68 and a beta of 0.45. The business’s 50 day moving average is $151.95 and its 200-day moving average is $152.23. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. Novartis AG has a 1-year low of $112.34 and a 1-year high of $170.46.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion during the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. Equities research analysts predict that Novartis AG will post 8.77 earnings per share for the current year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.